Research programme: remyelinating monoclonal antibodies - Acorda Therapeutics/Mayo Clinic

Drug Profile

Research programme: remyelinating monoclonal antibodies - Acorda Therapeutics/Mayo Clinic

Alternative Names: 94.03; M1 monoclonal antibodies; Remyelinating MAbs; Remyelination programme; SCH79.08; SCH94.03; SCH94.32; sHIgM46

Latest Information Update: 30 Apr 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mayo Clinic
  • Developer Acorda Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Myelin protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Multiple sclerosis
  • No development reported Spinal cord injuries

Most Recent Events

  • 23 Apr 2013 The lead candidate from this programme, rHIgM22, enters phase I trials for Multiple sclerosis
  • 16 Feb 2012 This programme is still in active development
  • 31 Dec 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top